Literature DB >> 14557656

Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.

Moraima Guadalupe1, Elizabeth Reay, Sumathi Sankaran, Thomas Prindiville, Jason Flamm, Andrew McNeil, Satya Dandekar.   

Abstract

Gut-associated lymphoid tissue (GALT) harbors the majority of T lymphocytes in the body and is an important target for human immunodeficiency virus type 1 (HIV-1). We analyzed longitudinal jejunal biopsy samples from HIV-1-infected patients, during both primary and chronic stages of HIV-1 infection, prior to and following the initiation of highly active antiretroviral therapy (HAART) to determine the onset of CD4(+) T-cell depletion and the effect of HAART on the restoration of CD4(+) T cells in GALT. Severe depletion of intestinal CD4(+) T cells occurred during primary HIV-1 infection. Our results showed that the restoration of intestinal CD4(+) T cells following HAART in chronically HIV-1-infected patients was substantially delayed and incomplete. In contrast, initiation of HAART during early stages of infection resulted in near-complete restoration of intestinal CD4(+) T cells, despite the delay in comparison to peripheral blood CD4(+) T-cell recovery. DNA microarray analysis of gene expression profiles and flow-cytometric analysis of lymphocyte homing and cell proliferation markers demonstrated that cell trafficking to GALT and not local proliferation contributed to CD4(+) T-cell restoration. Evaluation of jejunal biopsy samples from long-term HIV-1-infected nonprogressors showed maintenance of normal CD4(+) T-cell levels in both GALT and peripheral blood. Our results demonstrate that near-complete restoration of mucosal immune system can be achieved by initiating HAART early in HIV-1 infection. Monitoring of the restoration and/or maintenance of CD4(+) T cells in GALT provides a more accurate assessment of the efficacy of antiviral host immune responses as well as HAART.

Entities:  

Mesh:

Year:  2003        PMID: 14557656      PMCID: PMC229357          DOI: 10.1128/jvi.77.21.11708-11717.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

2.  Suppression of immune responses by CD8 cells. I. Superantigen-activated CD8 cells induce unidirectional Fas-mediated apoptosis of antigen-activated CD4 cells.

Authors:  A Noble; G A Pestano; H Cantor
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

3.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Authors:  E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker
Journal:  Science       Date:  1997-11-21       Impact factor: 47.728

4.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.

Authors:  R S Veazey; M DeMaria; L V Chalifoux; D E Shvetz; D R Pauley; H L Knight; M Rosenzweig; R P Johnson; R C Desrosiers; A A Lackner
Journal:  Science       Date:  1998-04-17       Impact factor: 47.728

5.  Programmed death of T cells in HIV-1 infection.

Authors:  L Meyaard; S A Otto; R R Jonker; M J Mijnster; R P Keet; F Miedema
Journal:  Science       Date:  1992-07-10       Impact factor: 47.728

6.  Primary acute simian immunodeficiency virus infection of intestinal lymphoid tissue is associated with gastrointestinal dysfunction.

Authors:  C Heise; C J Miller; A Lackner; S Dandekar
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

7.  Cytokine gene expression in HIV-infected intestinal mucosa.

Authors:  I McGowan; G Radford-Smith; D P Jewell
Journal:  AIDS       Date:  1994-11       Impact factor: 4.177

8.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Authors:  M M Lederman; E Connick; A Landay; D R Kuritzkes; J Spritzler; M St Clair; B L Kotzin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; M Wade; J D Roe; A Martinez; H Kessler
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

9.  Intestinal intraepithelial lymphocytes are primed for gamma interferon and MIP-1beta expression and display antiviral cytotoxic activity despite severe CD4(+) T-cell depletion in primary simian immunodeficiency virus infection.

Authors:  J J Mattapallil; Z Smit-McBride; M McChesney; S Dandekar
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

10.  Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group.

Authors:  T Schneider; H U Jahn; W Schmidt; E O Riecken; M Zeitz; R Ullrich
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

View more
  426 in total

Review 1.  Control of antiviral immunity by pattern recognition and the microbiome.

Authors:  Iris K Pang; Akiko Iwasaki
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.

Authors:  Jean-Philippe Herbeuval; Jakob Nilsson; Adriano Boasso; Andrew W Hardy; Michael J Kruhlak; Stephanie A Anderson; Matthew J Dolan; Michel Dy; Jan Andersson; Gene M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

Review 3.  HIV and inflammation: mechanisms and consequences.

Authors:  Peter W Hunt
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

4.  Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.

Authors:  April L Ferre; Donna Lemongello; Peter W Hunt; Megan M Morris; Juan Carlos Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

5.  On high alert.

Authors:  Emma Marris
Journal:  Nature       Date:  2010-07-15       Impact factor: 49.962

Review 6.  Tissue issues: mucosal T-cell responses in HIV-1 infection.

Authors:  Barbara L Shacklett; April L Ferre; Brenna E Kiniry
Journal:  Curr Opin HIV AIDS       Date:  2019-03       Impact factor: 4.283

7.  A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells.

Authors:  Steven A Yukl; Elizabeth Sinclair; Ma Somsouk; Peter W Hunt; Lorrie Epling; Maudi Killian; Valerie Girling; Peilin Li; Diane V Havlir; Steven G Deeks; Joseph K Wong; Hiroyu Hatano
Journal:  AIDS       Date:  2014-01-28       Impact factor: 4.177

8.  Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection.

Authors:  Adriano Boasso; Monica Vaccari; Anna Hryniewicz; Dietmar Fuchs; Janos Nacsa; Valentina Cecchinato; Jan Andersson; Genoveffa Franchini; Gene M Shearer; Claire Chougnet
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

Review 9.  HIV infection and the gastrointestinal immune system.

Authors:  J M Brenchley; D C Douek
Journal:  Mucosal Immunol       Date:  2008-01       Impact factor: 7.313

10.  CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection.

Authors:  M Vaccari; A Boasso; Z-M Ma; V Cecchinato; D Venzon; M N Doster; W P Tsai; G M Shearer; D Fuchs; B K Felber; G N Pavlakis; C J Miller; G Franchini
Journal:  Mucosal Immunol       Date:  2008-09-17       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.